Kenvue Inc. (NYSE:KVUE) Given Average Recommendation of "Hold" by Analysts

Shares of Kenvue Inc. (NYSE:KVUE - Get Free Report) have been given an average recommendation of "Hold" by the twelve brokerages that are presently covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $25.33.

A number of research firms recently weighed in on KVUE. Evercore ISI initiated coverage on Kenvue in a report on Monday, March 24th. They set an "in-line" rating and a $25.00 price target for the company. Canaccord Genuity Group raised their price target on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. UBS Group upped their price objective on Kenvue from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Friday, May 9th. Piper Sandler increased their price target on shares of Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research report on Monday, February 24th. Finally, Citigroup increased their target price on shares of Kenvue from $22.00 to $24.50 and gave the stock a "neutral" rating in a report on Friday, May 9th.

Kenvue Price Performance

Shares of KVUE stock traded down $0.37 during mid-day trading on Friday, reaching $23.57. The company's stock had a trading volume of 4,930,306 shares, compared to its average volume of 16,305,860. Kenvue has a 1-year low of $17.67 and a 1-year high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a market cap of $45.21 billion, a P/E ratio of 44.45, a PEG ratio of 2.62 and a beta of 1.02. The firm's 50-day moving average is $23.25 and its two-hundred day moving average is $22.63.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.01. The firm had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. The business's revenue for the quarter was down 3.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.28 earnings per share. On average, research analysts predict that Kenvue will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be given a dividend of $0.205 per share. The ex-dividend date is Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.48%. Kenvue's payout ratio is 149.09%.

Institutional Investors Weigh In On Kenvue

Institutional investors and hedge funds have recently made changes to their positions in the business. Merit Financial Group LLC purchased a new stake in Kenvue in the 4th quarter worth about $237,000. HB Wealth Management LLC lifted its stake in shares of Kenvue by 41.9% during the 4th quarter. HB Wealth Management LLC now owns 18,088 shares of the company's stock valued at $386,000 after buying an additional 5,343 shares in the last quarter. UMB Bank n.a. grew its stake in Kenvue by 184.3% in the 4th quarter. UMB Bank n.a. now owns 3,651 shares of the company's stock valued at $78,000 after buying an additional 2,367 shares in the last quarter. LaFleur & Godfrey LLC grew its holdings in Kenvue by 29.8% during the 4th quarter. LaFleur & Godfrey LLC now owns 81,300 shares of the company's stock valued at $1,736,000 after buying an additional 18,650 shares in the last quarter. Finally, Atomi Financial Group Inc. boosted its position in shares of Kenvue by 28.1% in the fourth quarter. Atomi Financial Group Inc. now owns 11,730 shares of the company's stock valued at $250,000 after acquiring an additional 2,571 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.